LeMaitre Vascular

LMAT

Market cap $2.45B

LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program.

BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.

LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript

BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance.

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

High coverage ratios and earnings growth make CAH, LTH, LMAT and FLS safer investment bets heading into 2026.

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.

BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.